Journal
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
Volume 14, Issue 3, Pages 568-586Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.4251/wjgo.v14.i3.568
Keywords
Barrett's esophagus; Endoscopic eradication therapy; Dysplasia; Adenocarcinoma; Natural history; Radiofrequency ablation
Categories
Ask authors/readers for more resources
Barrett's esophagus is the precursor to esophageal adenocarcinoma and has a stepwise progression. The risk of progression is extremely low in non-dysplastic Barrett's, interventions are not justified. The risk of cancer progression in low-grade dysplasia is between 1%-3%, and endoscopic eradication therapy (EET) can be considered. High-grade dysplasia has a yearly progression risk of 5%-10%, and EET is similarly effective to surgery and should be routinely performed. In intramucosal cancer, the risk of nodal metastases is comparable to operative mortality rate, making EET the preferred treatment. Surgery remains the standard of care for submucosal cancer, except in select situations.
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Progression to cancer typically occurs in a stepwise fashion through worsening dysplasia and ultimately, invasive neoplasia. Established EAC with deep involvement of the esophageal wall and/or metastatic disease is invariably associated with poor long-term survival rates. This guides the rationale of surveillance of Barrett's in an attempt to treat lesions at an earlier, and potentially curative stage. The last two decades have seen a paradigm shift in management of Barrett's with rapid expansion in the role of endoscopic eradication therapy (EET) for management of dysplastic and early neoplastic BE, and there have been substantial changes to international consensus guidelines for management of early BE based on evolving evidence. This review aims to assist the physician in the therapeutic decision-making process with patients by comprehensive review and summary of literature surrounding natural history of Barrett's by histological stage, and the effectiveness of interventions in attenuating the risk posed by its natural history. Key findings were as follows. Non-dysplastic Barrett's is associated with extremely low risk of progression, and interventions cannot be justified. The annual risk of cancer progression in low grade dysplasia is between 1%-3%; EET can be offered though evidence for its benefit remains confined to highly select settings. High-grade dysplasia progresses to cancer in 5%-10% per year; EET is similarly effective to and less morbid than surgery and should be routinely performed for this indication. Risk of nodal metastases in intramucosal cancer is 2%-4%, which is comparable to operative mortality rate, so EET is usually preferred. Submucosal cancer is associated with nodal metastases in 14%-41% hence surgery remains standard of care, except for select situations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available